Companies / FRE

FIREBRICK PHARMA LIMITED

ASX:FREPharmaceuticals, Biotechnology & Life Sciences
285.2M shares on issueASX (delayed) · as of 28 July 2026$0.027price · delayed$8.0Mmarket cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 46% in 24 months; 7 cash raises in 24 months

Cash runway1.4 quarters of funding
Share-count growth (24m)46.0%
Raise cadence (24m)7 cash raises
Options & rights overhang37.4% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

FIREBRICK PHARMA LIMITED's ordinary share count grew 46.0% between May 2024 and June 2026, to 285M shares. The company completed seven capital raises in that period for total disclosed proceeds of A$5.1M, most recently raising A$1.5M in March 2026. Options and rights on issue could convert into 107M new shares, equal to 37.4% of the current share count, with 0% in the money and the nearest expiry in September 2027. At the June 2026 quarter the company reported A$1.1M in available cash, equal to about 1.4 quarters of funding at recent rates. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
37.4%
Max option dilution
0.0%
ITM option dilution
3
Raises · last 12 months
1.4 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 285.2M per ASX (delayed) (28 July 2026).
225.9M247.7M269.4MDec 24Sept 25July 26Cash raise · 26 Mar 2026Cash raise · 15 Oct 2025Cash raise · 25 Aug 2025Cash raise · 23 June 2025Cash raise · 28 Mar 2025Cash raise · 27 Feb 2025

Cash runway

1.4 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$1.1M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
27 July 20263G · unquotedFRE : ORDINARY FULLY PAID285.2MAppendix 3G
1 June 20262A · quoted issueFRE : ORDINARY FULLY PAID285.2MAppendix 2A
31 May 20263H · cancellationFRE : ORDINARY FULLY PAID285.0MAppendix 3H
21 May 20262A · quoted issueFRE : ORDINARY FULLY PAID285.0MAppendix 2A
14 May 20262A · quoted issueFRE : ORDINARY FULLY PAID284.8MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

7 cash raises in the last 24 months · 3 in the last 12 months

$1.5M
Capital raise
26 Mar 2026
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

37.4%
Total overhang · of current shares
0.0%
In the money · at current price
106.7M
Potential new shares
Sept 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
20 May 2026Stephen Francis GoodallBuy110k—$5k3Y notice
20 May 2026Peter Laurence MolloyBuy245k—$10k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026Update - Notification regarding unquoted securities - FRE
26 July 2026$PInvestor Update
26 July 2026$PJune 2026 Quarterly Activity Report
14 July 2026Change of Address
22 June 2026Results of General Meeting
2 June 2026Nasodine Composition Patent Granted in New Zealand
1 June 2026Cleansing Notice
1 June 2026Application for quotation of securities - FRE
31 May 2026Proposed issue of securities - FRE
31 May 2026Notification of cessation of securities - FRE
29 May 2026Change in substantial holding
21 May 2026Notice of GM & Proxy Form & Access Letter
21 May 2026Cleansing Notice
21 May 2026Application for quotation of securities - FRE
21 May 2026Change of Director's Interest Notice - Peter Molloy
20 May 2026Change of Director's Interest Notice - Stephen Goodall
20 May 2026Close of Offer - Listing Options
14 May 2026Cleansing Prospectus - Listing of Options
14 May 2026Options Top 20 Holders Report
14 May 2026Options Range Report

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.